




References

REFERENCES

- Aboul- Enein, M.I.; Nasr, A.M.; Ahmed, A.A.; El-Diwany, O.; Hammouda, F.; Hindawy, D.S.; Kamel, A.M.; Hamaza, R.M. (1986):* Cytochemical profile of acute lymphoblastic leukemia classification by the new FAB. E.J. Egypt. Nat. Cancer Institute, 2: 325.
- Appleby, M.W. et al. (1992):* Defective T-cell receptor signaling in mice lacking the thymic isoform of P53 fyn. Cell, 70: 741.
- Armata, J.; Grzeskowiak, K.; Melanowska, J.; Balwierz, W.; Najbar-Pabian, A. and Pawlik, E. (1994):* Prognosis in acute lymphoblastic leukemia in children preceded by an aplastic phase. Leuk. Lymphoma., 13: 517.
- Aur, R.; Simone, J.; Husto, H. and Verzosa, M. (1992):* A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphoblastic leukemia. Cancer, 29: 382.
- Bailey, C.C. (1993):* Acute lymphoblastic leukemia in Wintrobe's clinical hematology. Forester J. et al (ed.) 9th edition.
- Bain, B.J. (1993):* Leukaemic diagnosis: A guide to the FAB classification. Gower Medical, London.
- Bain, B.J. and Catovsky, D. (1995):* Current concerns in haematology, 2. Classification of acute leukaemia. Journal of Clinical Pathology, 43: 882-887.
- Barrett, A.; Horowitz, M.; Pollock, B. et al. (1994):* Bone marrow transplant from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in second remission. N. Engl. J. Med., 331: 1253.
- Beltinger, C.; Kurz, E.; Bohler, T.; Schrappe, M.; Ludwig, W.D. and Debatin, K.M. (1998):* CD95 (APOI/Fas) mutation in childhood T-lineage acute lymphoblastic leukaemia. Blood, May 15; 91(10): 3943-51.

Bernadette, F. and Rodak (1995): Leucocyte disorder and ancillary studies? *Diagnostic Hematology*, 27: 402.

Bernstein, M.; Whitehead, V.; Devine, S. et al. (1993): Ifosfamide with mesna uro-protection and etoposide in recurrent, refractory acute leukemia in childhood. A pediatric oncology group study cancer, 72: 1790.

Bertoni, F.; Conconi, A.; Luminari, S.; Realini, C.; Roggero, E.; Baldini, S. and Neri, A. (2000): Lack of CD95/Fas gene somatic mutation in extranodal, nodal and splenic marginal zone B-cell lymphoma. *Leukemia* (14) 3: 446-448.

Bessho, F.; Kinumaki, H.; Yokota, S.; Hayashi, Y.; Kobayashi, M.; Kamoshita, S. (1994): Liver function studies in children with acute lymphocytic leukemia after cessation of therapy. *Med. Pediatr. Oncol.*, 23: 111.

Blany, S. and Poplack, D. (1996): Pharmacologic strategies for treatment of meningeal malignancy. *Investg. New Drugs* (in press).

Bleyer, W. (1988): Central nervous system leukemia. *Ped. Clin. North Am.*, 35: 789.

Bleyer, W.; Sather, H.; Coccia, P.; Lukens, J.; Siegel, S. and Wammond, G. (1986): The staging of childhood acute lymphoblastic leukemia: strategies of the children's cancer study group and a three-dimensional technique of multivariate analysis. *Med. Pediatr. Oncol.*, 14: 271.

Bleyer, W.; Sather, H.; Nickerson, H. et al. (1991): Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low risk childhood acute lymphoblastic leukemia a report of the CCG-161 study by the children's cancer study group. *J. Clin. Oncol.*, 9: 1012.

Brecher, M. (1986): Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse. *Cancer*, 58: 1024.

Buhrer, C.; Hartmann, R.; Fengler, R. et al. (1994): Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. *Blood*; 83: 3468.

Bunin, N.J.; Pui, C.H. (1985): Differing complication of hyperleukocytosis in children with acute lymphoblastic or acute non lymphoblastic leukemia. *J. Clin. Oncol.*, 3: 1590.

Campana, D. and Beham, F. (1992): Leukemia immunophenotyping: uses for establishing diagnosis predicting outcome and assessing treatment response in Whittaker J. (ed) leukemia 2nd. Ed. London Blackwell Scientific Publications, P. 203.

Campana, D.; Pui, C.H. (1995): Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. *Blood*, 85: 1416.

Campana, D.; Hansen-Hagge, T.E. and Matutes, E. (1990): Phenotypic, genotypic, cytochemical and ultrastructural characterization of acute undifferentiated leukemia. *Leukemia*; 4: 620-24.

Carbonell, E.; Swansbury, J. and Min, T. (1996): Cytogenetic findings in acute biphenotypic leukemia. *Leukemia*; 10: 1283-87.

Carbrera, M.E. (1990): Immunologic classification of acute lymphoblastic leukemia. *Am. J. Pediatr. Hematology Oncol.*, 12: 283.

Cartwright, R. (1992): Epidemiology. In: Whitlaker J. (ed): *Leukemia* 2nd ed., London, Blackwell Scientific Publications.

Cascino, T. et al. (1995): Three function soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. *J. Immunol.*, 154: 2706-2713.

Casper, J.; Camitta, B. and Truitt, R. (1995): Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. *Blood*, 85: 2354.

Cetovsky, D. and Foa, R. (1990):
The lymphoid leukemia. Butter Worth London.

Chan, J.; Becher, F; German, J. and Ray, J. (1987): Altered DNA ligase I activity in Bloom's syndrome cell. *Nature*, 325: 357.

- Chao, N.; Forman, S. and Schmind, G. (1991):** Allogenic bone marrow transplantation for high risk acute lymphoblastic leukemia during first complete remission. *Blood*, 76: 1923.
- Cheng, J.; Zhou, T.; Liu, C.; Shaprio, J.P.; Brauer, M.J.; Kiefer, M.C.; Barr, P.J. and Mountz, J.P. (1994):** Protection from Fas mediated apoptosis by a soluble form of the Fas molecule. *Science*, 263: 1759-1762.
- Chessells, J. (1994):** Central nervous system directed therapy in acute lymphoblastic leukemia. *Clin. Hematol.*, 7: 349.
- Chessells, J.; Eden, O.; Bailey, C.; Lilleyman, J.; Richards, S. (1994):** Acute lymphoblastic leukemia in infancy: experience in MRC UKALL trials report from the medical research council working party on childhood leukemia. *Leukemia*, 8: 1275.
- Cohen, J.J. (1994):** Apoptosis: physiologic cell death. *J. Lab. Clin. Med.*, 124: 761.
- Cotron, R.S.; Kumar, V. and Robbins, S.L. (Eds) (1994):** Robbins pathologic Basis of Disease (5th ed.) W.B. Saunders Company, P. 35 and 648.
- Creutzig, L.L.; Ritter, J. and Schellong, G. (1990):** Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. *Blood*; 75: 1932.
- Crist, W.; Boyell, J.; Jackson, J.; Vietti, T.; Borowitz, M.; Chauvenet, A.; Winick, N.; Ragab, A.; Mahoney, D. and Head, D. (1989):** Prognostic importance of the pre B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia a pediatric Oncology Group Study. *Blood*, 74: 1252.
- Crist, W.; Pullen, J.; Boyett, J. et al. (1988):** Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis. A pediatric oncology group study. *J. Clin. Oncol.*, 6: 34.

- Debatin, K.M. (1994):** APO-1 (CD95) and BCL-2. Determinant of cell death in the human thymus. *Res. Immunol.*, 56: 30-35.
- Debatin, K.M.; Fahrig-Faissner, A.; Enenkel-Stoodt, S.; Kreuz, W.; Benner, A. and Krammer, P.H. (1994):** High expression of APO-1 (CD95) on T-lymphocyte from HIV-1 infected children. *Blood*, 83: 3101.
- Debatin, K.M.; Goldman, C.K. et al. (1993):** APO-1 induced apoptosis of leukemia cells from patients with adult cell leukemia. *Blood*, 81: 2972.
- Debatin, R.M. and Krammer, P.H. (1995):** Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent antiapoptotic program. *Leukaemia*, May, 9(5): 815-20.
- Donald, H.; Mahoney, Samuel Hellman, Steven, A. et al. (1996):** Cancer principles and practice of oncology. Devita, 96: 1565.
- Dow, L.; Change, L.; Tsiatis, A.; Meluin, S. and Bowman, W. (1992):** Relationship of pretreatment lymphoblastic proliferative activity and prognosis in 97 children with acute lymphoblastic leukemia. *Blood*, 59: 1197.
- Eden, O.; Lilleyman, J. and Richard, S. (1991):** Result of medical research council childhood leukemia trial MK ALL VIII. *Br. J. Hematol.*, 78: 187-196.
- El-Beshlawy, A.; Mokhtar, N.; Shams El-Din, A.; Kamel, M.; Abou-Alam, M.; Kaddak, N.; Ragab, L.; Abdel-Hadi, S. and Badawi, A. (1989):** The immunological phenotypes of ALL in Egyptian Children in correlation to clinical laboratory findings. *Pediatric Oncology Symposium*, National Cancer Institute, Cairo University, Cairo Meridian.
- El-Haddad, A. (1986):** The effect of combination chemotherapy on neutrophil functions and its impact on prognosis in ALL in Egyptian children M.D. thesis in Pediatric Oncology National Cancer Institute, Cairo University.

- Emerit, I.; Lavy, A.; Pagano, G.; Pinto, L.; Calzona, R. and Zatterele, A. (1995):** Transferable clastogenesis activity in plasma from patient with Fanconi anemia. *Hum. Genet.*, 96: 14.
- Evans, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Hartmut, L., Brooks, M., and Hancock, D. (1992) :** Induction of apoptosis in fibroblast by c.myc protein. *Cell*; 69 : 119 : 128.
- Finklestein, J.; Miller, D.; Feusner, J. et al. (1994):** Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the children's cancer group? *Cancer*, 73: 219.
- Flak, M.H.; Trauth, B.C.; Debatin, K.M.; Klas, C.; Gregory, C.D.; Rickinsen, A.B.; Calender, A.; Lenoir, G.M.; Ellwart, J.W.; Krammer, P.H. and Bornkamm, G.W. (1992):** Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. *Blood*, 79: 3300-3306.
- Foon, K.A.; Gale, R.P. and Todd, R.F. III (1990):** Immunologic advances in classification of leukemia. In: Mauer AM (ed): *The biology of human leukemia*. P: 44, Johns Hopkins University Press, Baltimore.
- Frank, M.; Balis, Jobs Tlocenberg, David, G.; Polpack, et al. (1993):** Principle and practice of pediatric oncology. Pizzo.
- Friesen, C.; Fulda, S. and Debatin, K.M. (1997):** Deficient activation of CD95 (APO-1/Fas) system in drug resistant cells. *Leukemia* (11): 1833-41.
- Friesen, C.; Herr, I.; Krammer, P.H. and Debatin, K.M. (1997):** Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemic cells. *Nat. Med.* May, 2(5): 574-7.
- Gadalla, A. (1996):** Profile of childhood cancer in the National Cancer Institute from 1975-1994. M.Sc. Thesis of Pediatric, National Cancer Institute, Cairo University.

- Gagnon, G.A.; Childs, C.C. and LeMaistre, A. (1989):** Molecular heterogeneity in acute leukemia lineage switch. *Blood*; 74: 2088-95.
- Gaynon, P.; Bleyer, W.; Steinherz, P. et al. (1990):** Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. *Med. Pediatr. Oncol.*, 18: 273.
- Gelber, R.; Sallan, S.; Cohen, H. et al. (1993):** Central nervous system treatment in children acute lymphoblastic leukemia long term follow up of patients diagnosed between 1973 and 1985. *Cancer*, 73: 261.
- Goldman, J.M.; Schmitz, N.; Niethammer, D. et al. (1998):** Allogenic and autologous transplanation for haematological disease solid tumors and immune disorders? Current Practice in Europe in 1998. *Bone Marrow Transplantation*, 21: 1-7.
- Gorin, N.C.; Aegerter, P. and Aubert, B. (1990):** Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. *Blood*, 75: 1606.
- Greaves, M.F.; Brown, G.; Rapson, N.T. and Lister, T.A. (1975):** Antisera to acute lymphoblastic leukaemia cells. *Clin. Immunol. Immunopathol.*, 4: 67.
- Gurney, J.G.; Severson, P.K.; Davis, S. et al. (1995):** Incidence of cancer in children in the United States. *Cancer*, 75: 2186.
- Hammond, D.; Sather, H.; Nesbit, M.; Miller, D.; Coccia, P.; Bleyer, A.; Lukens, J. and Siegel, S. (1986):** Analysis of prognostic factors in acute lymphoblastic leukemia. *Med. Pediatr. Oncol.*, 14: 124.
- Harutsumi, M.; Akazai, A.; Kitamura, T.; Manki, A.; Tanaka, H.; Oda, M.; Seino, Y. (1995):** A case of acute lymphoblastic leukemia accompanied with the production of parathyroid hormone related protein. *Miner Electrolyte Metab.*, 21: 171.
- Heaney, M.L. and Golde, D.W. (1996):** Soluble cytokine receptors. *Blood*, 87: 847-857.

- Henze, G.; Fengler, R.; Rieter, A.; Ritter, J. and Riehm, H. (1990):** Impact of early intensive reinduction therapy on event-free survival in children with low-risk ALL. *Haematol. Blood Transfusion*, 33: 483.
- Hinkle, A.; Dinndrof, P.; Bulas, D. and Kapur, S. (1994):** Relapse of acute lymphoblastic leukemia in the inferior rectus muscle of the eye. *Cancer*, 73: 1757.
- Howie, S.; Harrison, D.J. and Wyllie, A.H. (1994):** Lymphocyte apoptosis mechanisms and implication in disease. *Immunol. Rev.*, 142: 141-156.
- Hurwitz, C.A.; Mounce, K.G. and Grier, H.E. (1995):** Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. *J. Pediatric Hematol. Oncol.*, 17: 185.
- Hussein, M.H. (1983):** Clinico-epidemiologic study of acute lymphoblastic leukemia in Egyptian children. M.Sc. Thesis of Pediatrics, Cairo University.
- Inaba, H.; Komada, Y.; Li, Q.; Zhang, X.L.; Tanaka, S.; Azuma, E.; Yamamoto, N. and Sahurai, M. (1999):** mRNA expression of variant Fas molecules in acute leukemia cells. *Am. J. Hematol.*, 62(3): 150-8.
- Irisarri, M.; Plumas, J.; Bonnefoxi, T.; Jacob, M.C.; Roucard, C.; Pasquierm, A. and Sotto, J.J. (2000):** Resistance to CD95 mediated apoptosis through constitutive C-FLIP expression in non Hodgkin's lymphoma B-cell line. *Leukemia* (14): 3, 249-2158.
- Jakachi, R.; Larsen, R.; Barber, G.; Heyman, S.; Frideman, M. and Silber, J. (1993):** Comparison of cardiac function tests after anthracyclin therapy in childhood implication for screening. *Cancer*, 72: 2739.
- Jankovic, M.; Brouwers, P.; Valsecchi, M. et al. (1994):** Association of 1988 cGy irradiation with intellectual function in children with ALL. ISPACC: International Study Group on Psychosocial Aspects of Childhood Cancer. *Lancet*, 344: 2224.

- Jayabose, S.; Tugal, P. and Ruddy, R. (1991):** Transfusion therapy for sever anemia. Am. J. Pediatr. Hematol. Oncol., 13: 114.
- Jonsson, O. (1990):** Bone pain as an initial symptoms of childhood acute lymphoblastic leukemia. J. Ped., 117: 233.
- Judith, F.; Margolin, E., and David, G. et al. (1997):** Principles and practice of pediatric oncology. Pizzo, 409: 458.
- Kamihira, S.; Yamada, Y.; Tomonaga, M.; Sugahara, K. and Tsuruda, K. (1999):** Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukemia: Soluble Fas isoform is an independent risk factor for prognosis. British Journal of Hematology, 107: 851-860.
- Katwinsky, D.K.; Roberson, P.; Dahl, G. et al. (1985):** Clinical relevance of lymphoblastic biological features in children with acute lymphoblastic leukemia. J. Clin. Oncol., 3: 477.
- Katz, J.; Pollock, B.; Jacaruso, D. and Morad, A. (1993):** Final attained height in patients successfully treated for childhood acute lymphoblastic leukemia? J. Pediatr., 123: 546.
- Khalifa, A.; Mokhtar, G.; Gadallah, M. and El-Kasheer, I. (1988):** Clinico epidermiological study of acute childhood leukemia in Egypt. Egypt J. Hematol., 13: 167.
- King, L.B. and Ashwell, J.D. (1993):** Signaling for death of lymphoid cells. Curr. Opin. Immunol., 5: 368-373.
- Knipping, E.; Debatin, K.M.; Stricker, K.; Heilig, B.; Eder, A. and Krammer, P.H. (1995):** Identification of soluble APO-1 in supernatants of human B and T-cell lines and increased serum level in B and T-cell leukemia. Blood, 85: 1562-1569.
- Koizumi, S.; Shimizu, H.; Asami, K. et al. (1994):** Assessment of testicular biopsy after cessation of maintenance chemotherapy in childhood acute lymphoblastic leukemia: a report from children's cancer and leukemia study group. J. Hematol., 60: 137.

- Koury, M.J. (1992):** Programmed cell death (apoptosis) in hematopoiesis. *Exp. Hematol.*, 20: 391-394.
- Kovarik, P.; Shirt, M.; Yuen, B.; Radvany, R. and Schumacher, H. (1992):** Hand mirror variant of acute lymphoblastic leukemia: Evidence of mixed leukemia? *Am. J. Clin. Pathology*, 98: 526.
- Krammer, P.H.; Knipping, E.; Stricker, K.; Walzeak, H.; Behrman, I.; Mariani, S.; Matiba, B.; Fath, M.; Daniel, P.T.; Westendrop, M.O.; Dhein, J.; Baumler, C.; Hellbaidt, S.; Germer, M.; Peter, M.E. and Debatin, K.M. (1994):** The role of APO-1 mediated apoptosis in the immune system. *Immunol. Rev.*, 142: 175.
- Kumar, P.; Kun, L.; Husto, H. et al. (1995):** Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. *Int. J. Radiat. Oncol. Biol. Phys.*, 31: 477.
- Kurtzberg, J.; Graham, M.; Casey, J.; Olson, Stevens, C. and Kubinstein, P. (1994):** The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation. *Blood Cells*, 20: 275.
- Kushner, D.; Weinstein, H. and Kirkpatrick, J. (1980):** The radiological diagnosis of leukemia and lymphoma in children. *Semin. Roentgenol.*, 115: 316.
- Landowski, T.; Qu, N.; Buyuksal, I.; Painter, J. and Dalton, W.S. (1997):** Mutation in the Fas antigen in patients with multiple myeloma. *Blood*, 90: 4266-4270.
- Lanzkowisky, P. (ed) (1995):** Manual of pediatric hematology and oncology 2nd ed. Churchill Livingstone.
- Lauer, S.; Shuster, J. and Kirchner, P. (1994):** Significance of cerebrospinal lymphoblasts at diagnosis in children with acute lymphoblastic leukemia. *Proc. Am. Soc. Clin. Oncol.*, 13: 317.

- Leithauser, F.; Dhein, J.; Mechtersheimer, G.; Korets, K.; Bruderlein, S.; Henne, C.; Schmidt, A.; Debstin, K.M.; Krammer, P.H. and Moller, P. (1993):** Constitutive and induced expression of APO-1, new member of the nerve growth factor/ tumor necrosis receptor superfamily in normal and neoplastic cells. *Laboratory Investigation*, 69: 415-429.
- Lerkin, S.; Mirro, J.; Kureze, S. and Hongo, T. (1981):** Immunologic evaluation in the prognosis of ALL. *Blood*, 58: 501.
- Li, Q.; Tsuruda, K.; Sugahara, K.; Dateki, N.; Ohishi, E.; Yamada, Y.; Tomonga, M.; Moriuchi, H.; Tsuji, J. and Kamihira, S. (2000):** Qualitative and quantitative characterization of Fas (CD95) expression and its role in primary human acute leukemia cells. *Leuk. Res.*, 24(5): 437-444.
- Lichter, P.; Walczak, H.; Weitz, S.; Behrmann, I. and Krammer, P.H. (1992):** The human APO-1 antigen map to 10q²³, a region which is syntenic with mouse chromosome 19. *Genomics*, 14: 179.
- Liesner, R.J.; Leiper, A.D.; Hann, I.M. and Chessells, J.M. (1994):** Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. *J. Clin. Oncol.*, 12: 916.
- Lilleyman, J. and Lennard, L. (1994):** Mercaptopurine metabolism and risk of relapse childhood lymphoblastic leukemia. *Lancet*, 343: 1180.
- Lipshultz, S.; Colan, S.; Gelber, R. et al. (1991):** Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. *N. Engl. J. Med.*, 324: 808.
- Lobato-Mendizabel, E.; Ruiz-Arguelles, G. and Marinlopez, A. (1989):** Leukemia and nutrition. Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk. Acute. Lymphoblastic leukemia. *Leuk. Res.*, 13: 895.
- Loenan, W.A.; deVries, E.; Gravestien, L.A.; Hintzen, R.Q.; Van Lier, R.A. and Borst, J. (1992):** The CD27 membrane receptor, a lymphocyte specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. *Eur. J. Immunol.*, 22: 447.

- Lowell, C. (1997):** Fundamentals of blood cell biology. Medical Immunology, 16: 22-23.
- Ludwig, W.D.; Raghavacher, A. and Thiel, E. (1994):** Immunophenotypic classification of acute lymphoblastic leukemia. Bailliere clinical haematology, 7: 235.
- Ludwig, W.D.; Reiter, A.; Loffler, H. et al. (1994):** Immunophenotypic features of childhood and adult acute lymphoblastic leukemia. L experience of the German multicenter trials ALL. BFM and GMALL, leukemia, lymphoma; 13 (Suppl. 11): 71.
- Mahmoud, H.; Evans, W.; Liu, Q. et al. (1994):** Presence of leukemic blasts in CSF at diagnosis predict CNS relapse of childhood ALL. Med. Pediatr. Oncol., 23: 189.
- Mahoney, D.; Nitsch, R.; Lauer, S. et al. (1996):** Neurotoxicity in children with acute lymphoblastic leukemia receiving intensive methotrexate schedules. A pediatric oncology group study. Proc. Am. Soc. Clin. Oncol., 14.
- Malcomson, R.D.G.; Clarke, A.R.; Peter, A.; Coutts, S.B.; Howie, S.E.M. and Harison, D.J. (1997):** Apoptosis induced by γ -irradiation, but not CD4 ligation, of peripheral T-lymphocytes in vivo is p53-dependent. J. Pathol., 181: 166.
- Marco, Z.; Andrea, P.; Chiara, M.; Federico, B. et al. (1999):** Total body irradiation, thiotepa and Cyclophosphamide as a conditioning regimen for children with ALL in first or second remission undergoing BMT with HLA-identical siblings. Journal of Clin. Oncol., 17: 1838.
- Margolin, J.F. and Poplack, D.G. (1997):** Acute lymphoblastic leukemia in: Pizzo P.A., Poplack DG (eds): practice of pediatric Oncology, Chapter 17: 409 3rd ed. Philadelphia, JB Lippincott.
- Matherly, L.; Taub, J. and Ravindranathy (1995):** Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in children acute lymphoblastic leukemia. Blood, 85: 500.

- Matutes, E.; Buccheri, V. and Morilla, R. (1993):** Immunological, ultrastructural and molecular features of unclassifiable acute leukemia. *Recent Results Cancer Res.*, 131: 41-52.
- Mauer, A.M. (1995):** Acute lymphoblastic leukemia. In Williams Haematology, By Beutler, E., Lichtman, M.A., Collier, B.S. and Kipps, T.J. (eds) 5th ed. McGraw-Hill, Inc. Health Professions Divisions, P. 1004.
- McClanik, K.; Leach, C.; Jenson, H. et al. (1995):** Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. *N. Engl. J. Med.*, 332: 12.
- McConkey, D.J.; Jondal, M. and Orremus, S. (1992):** Cellular signaling in thymocyte apoptosis. *Semin. Immunol.*, 4: 371.
- Migliorati, G., Nicoletti, I., Grocicchio, F., et al. (1992) :** Heat shock induces opoptosis in mouse thymocytes and protect them from glucocorticoid- induced cell death. *Cell Immunol.*, 143 : 348-356.
- Miller, D.R.; Krailo, M. and Bleyer, W.A. (1985):** Prognostic implication of blast cell morphology in childhood acute lymphoblastic leukemia. A report from the children's cancer. Study group cancer treat, Rep., 69: 1211.
- Miller, D.R.; Leikin, S.; Albo, V. et al. (1981):** Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukemia. *Br. J. Haematol.*, 48: 199.
- Minegishi, M.; Minegishi, N.; Yanagisawa, T. et al. (1995):** A human CD4-CD8-T-cell receptor alpha beta + T-leukaemic cell line undergoing phyohemagglutination-induced apoptosis. *Leuk. Res.*, 19(7): 433-42.

- Munker, R.; Midis, G.; Owen-Schaub, L. and Andreff, M. (1996):** Soluble Fas is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. *Leukemia* 10(9): 1521-30.
- Nagata, S. and Goldstein, P. (1995):** The Fas death factor. *Science*, 267: 1449-1456.
- Neglia, J.; Meadow, A.; Robison, L. et al. (1991):** Second neoplasms after acute lymphoblastic leukemia in children. *N. Engl. Med.*, 325: 1330.
- Neglia, J.; Robison, L. (1988):** Epidemiology of acute lymphoblastic leukemia. *Pediatr. Clin. North Am.*, 35: 675.
- Nicholson, D.W. (1995):** Identification and inhibition of ICE/CED-3 protease necessary for mammalian apoptosis. *Nature*, 376: 37-43.
- Ogasawara, J.; Suda, T. and Nagata, S. (1995):** Selective apoptosis of CD4⁺ CD8⁺ thymocytes by the anti-Fas antibody. *Journal of Experimental Medicine*, 181: 485-491.
- Ohno, R.; Tomonaga, M.; Kotayaki (1990):** Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. *N. Engl. J. Med.*, 323: 871.
- Orlando, Grune and Stratton (1994):** The acute toxicity's of chemotherapy.
- Owen-Schaub, L.B.; Melerissian, S. and Ford, R.J. (1993):** Fas/APO-1 expression and function on malignant cells of hematologic and non hematologic origin. *J. Immunother.*, 14: 234-241.

- Parkin, D.; Stiller, C. and Draper, G. (1988):** International incidence of children cancer, IARC scientific publication. No. 67; Lyon France.
- Papoff, G.; Cascino, I.; Erano, A.; Shroce, G.; Lynch, D.H. and Rubern, G. (1996):** An N-terminal domain shared by Fas/APO-1 (CD95) soluble variants prevent cell death in vitro. *Journal of Immunology*, 156: 4622-4630.
- Pendergrass, T. (1985):** Epidemiology of acute lymphoblastic leukemias. *Semin. Oncol.*, 12: 80.
- Pendergrass, T.; Hoover, R. and Godwin, J. (1985):** Prognosis of black children with acute lymphoblastic leukemia. *Med. Pediatr. Oncol.*, 1: 143.
- Philip (2000):** Manual of pediatric haematology and oncology. *Leukemia* 141: 359-411.
- Poplack, D. (1985):** Acute lymphoblastic leukemia in childhood. *Pediatr. Clin. North Am.*, 32: 669.
- Poplack, D. and Brouwers, P. (1989):** Sequelae of central nervous system therapy. *Clin. Oncol.*, 4: 263.
- Poplack, D.; David, G. and Philip, A. (1993):** Treatment of childhood acute lymphoblastic leukemia. *Blood*, 33: 892.
- Poussaint, T.; Siffert, J.; Barnes, P. et al. (1995):** Hemorrhagic vasculopathy after treatment of central nervous system neoplasia in childhood diagnosis and follow up. *AJNR Am. J. Neuroradiol.*, 16: 693.
- Preston, D.; Kusumi, S.; Tomonago, M.; Izumi, S.; Ron, E.; Kuramoto, A.; Kamada, N.; Dohy, H. and Mastuo, T. (1994):** Cancer incidence in atomic bomb survivor. Part II, Leukemia, lymphoma and multiple myeloma 1950-1987, *Radiat. Res.*, 137: 68.
- Price, R. (1983):** Therapy related CNS disease in children with acute lymphoblastic leukemia. In: Mastrangelo, R., Poplack, D. and Riccardi, R. (eds). *CNS Leukemia Prevention and treatment*. Boston, Martinus Nijhoff.

- Pui, C.H. (1995):** Childhood leukemias. *N. Engl. J. Med.*, 332: 1618.
- Pui, C.H. (1998):** Recent advances in the biology and treatment of acute lymphoblastic leukemia. *Curr. Opin. Hematol.*, 5: 992-301.
- Pui, C.H.; Behm, F.; Singh, B. et al. (1990):** Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. *Blood*, 75: 174.
- Pui, C.H.; Boyett, J.; Hancock, M.; Pratt, C.B.; Meyer, W.H. and Crist, M.W. (1995):** Outcome of treatment for childhood cancer in black as compared with white children. *JAMA*, 273: 633.
- Pui, C.H.; Ribeiro, R.C.; Campana, D.; Raimondi, C.C.; Hancock, M.L.; Behm, F.G.; Sandlund, J.T.; Rivera, G.K.; Evans, W.E.; Crist, M.W. and Krance, R. (1996):** Prognostic factors in the acute lymphoid and myeloid leukemias of infant leukemia, 10: 952.
- Pullen, J.; Boyett, J.; Borowitz, M. et al. (1987):** How important is common acute lymphoblastic leukemia antigen negativity as a prognostic factor in children excluding infants with B-precursor acute lymphoblastic leukemia: a pediatric oncology group study abstract 595? *Proc. Am. Soc. Clin. Oncol.*, 6: 151.
- Raimondi, S.E.; Pullen, A. and Rautoneu, A. (1993):** Cytogenetic of pre-B cell ALL with emphasis in prognostic implication of t(1: 19). *J. Clin. Oncol.*, 8: 1380.
- Reaman, G. (1989):** Intensive systemic and intrathecal chemotherapy for infant with acute lymphoblastic leukemia. *Proc. Am. Soc. Clin. Oncol.*, 8: 24.
- Reaman, G.; Zeltzer, P.; Bleyer, W.; Amendola, B.; Level, C.; Sather, H.; Hammond, D. (1985):** Acute lymphoblastic leukaemia in infant less than one year of age: accumulative experience of the children's Cancer Study Group. *J. Clin. Oncol.*, 3: 1513.
- Reaman, G.H.; Sposto, R.; Sensel, M.G.; Lange, B.J.; Leonard, M.; Holmes, E.J.; Pendergrass, T.W.; Brien, R. and Trigg, M.E. (1999):** Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the children's cancer group. *J. Clin. Oncol.*, 17: 445-55.

- Reed, J.C. (1995):** BCL-2: prevention of apoptosis as a mechanism of drug resistance. *Hematol. Oncol. Clin. North Am.*, 9: 451.
- Reilly, J.; Odam, I.; McColl, J.; McAllister, P.; Gibson, B. and Whatron, B. (1994):** Dose weight for height have prognostic significance in children with ALL? *Am. J. Pediatric, Hematology Oncology*, 16: 225.
- Reiter, A.; Schrappe, M.; Ludwig, W.D. et al. (1994):** Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multi-center trial ALL-BFM 86. *Blood*, 84: 312.
- Ries, L.A.G.; Miller, B.A.; Hankey, B.F. et al. (1994):** Cancer statistics Review 1973-1991: tables and Graphs, Bethesda, MD: National Cancer Institute, Publication # NIH, 2789.
- Rieux-Laucat, F.; Le-Desit, F.; Hivroz, C.; Roberts, I.A.G.; Debatin, K.M.; Fischer, A. and DeVillartay, J.P. (1995):** Mutation in Fas as associated with human lymphoproliferative syndrome and autoimmunity. *Science*, 268: 1347-1349.
- Rivera, G.; Pinke, D.; Simone, J.; Hancock, M.; Crist, W. (1993):** Treatment of acute lymphoblastic leukemia: 30 years experience at St. Jude Children's research hospital. *N. Engl. J. Med.*, 329: 1289.
- Romana, S.; Poirel, H.; Leconiat, M. et al. (1995):** High frequency of t(12; 21) in childhood B lineage acute lymphoblastic leukemia. *Blood*, 11: 4263.
- Ross, J.; Davis, S.; Potter, J. and Robison, L. (1994):** Epidemiology of childhood leukemia with a focus of infants. *Epidemiologic Reviews*, 16: 243.
- Rubin, E. and Farber, J.L. (1994):** Pathology (2nd ed.), J.P. Lippincott Comp., p. 32.
- Sachs, L. and Lotem, J. (1993):** Control of programmed cell death in normal and leukemic cells: New implications for therapy. *Blood*, 82(1): 15-21.

- Sather, H. (1986):** Age at diagnosis of childhood acute lymphoblastic leukemia. *Med. Pediatr. Oncol.*, 14: 166.
- Schorin, M.; Blattner, S.; Gelber, R. et al. (1994):** Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/ Children's Hospital Acute lymphoblastic leukemia Consortium protocol 85-01. *J. Clin. Oncol.*, 12: 740.
- Schuler, D. and Szende, B. (1998):** Apoptosis and acute lymphocytic leukemia in children. *J. Cell Biol.*, (5): 28-34.
- Schumacher, H.R.; Perlin, E. and Klos, J.R. (1979):** Hand-mirror cell leukemia, a new clinical and morphological variant. *Am. J. Clin. Path.*, 68: 531.
- Shu, X.O.; Ross, J.; Pendergrass, T.; Reaman, G.; Lampkin, B. and Robison, L. (1996):** Parental alcohol consumption, cigarette smoking and risk of infants leukemia: a childrens cancer group study. *J. Nat. Cancer Inst.*, 88: 24.
- Seiter, K., (2001) :** Acute lymphoblastic leukemia. *Medical Journal* June (2) 1-24.
- Shuster, J.; Falletta, J.; Pullen, J.; Crist, W.; Humphrey, G.; Dowell, B.; Wharam, M. and Borowitz, M. (1990):** Prognostic factors in childhood T-cell Acute lymphoblastic leukemia. *Pediatric Oncology Group Study Blood*, 75: 166.
- Sidhom, I. (1998):** Station specific therapy of acute lymphoblastic leukemia in children. M.D. Thesis in Pediatric Oncology, National Cancer Institute Cairo University.
- Silverman, L.B. and Weinstein, H.J. (1997):** Treatment of childhood leukemia. *Curr. Opin. Oncol.*, 9: 26-33.
- Smith, J.; Arthur, D.; Camitta, B. et al. (1996):** Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. *J. Clin. Oncol.*, 14: 18.

- Smith, S.; Wofford, M.; Shuster, J. and Rivera, G. (1990):** Treatment of testicular leukemia in children of lymphoblastic leukemia (ALL): a pediatric oncology group study. *Pro. Am. Soc. Oncol.*, 9: 841.
- Stass, S.A. and Mirro, J.Jr. (1986):** Lineage heterogeneity in acute leukemia: Acute mixed-lineage leukemia and lineage switch. *Clin. Haematol.*, 3: 811.
- Stass, S.A.; Pui, C.H. and Mevin, S. (1984):** Sudan Black B positive acute lymphoblastic leukemia. *Br. J. Haematol.*, 57: 413.
- Steinherz, P.; Gaynon, P.; Breneman, J. et al. (1996):** Cytoreduction and prognosis in acute lymphoblastic leukemia the importance of early marrow response report from the children's cancer group. *J. Clin. Oncol.*, 14: 389.
- Sugahara, K.; Yamada, Y.; Hirakata, Y.; Matsuo, Y.; Tsuruda, K.; Tomonaga, M.; Maeda, T.; Atogami, S.; Tsukasaki, K. and Kamihira, S. (1997):** Soluble and membrane isoforms of Fas (CD95) in Fresh Adult T-cell leukemia (ATL) cells and ATL-cell lines. *International Journal of Cancer*, 72: 128-132.
- Synold, T.; Relling, M.; Boyett, J. et al. (1994):** Blast cell methotrexate polyglutamate accumulation in vivo differs by lineage, ploidy and methotrexate dose in acute lymphoblastic leukemia. *J. Clin. Invest.*, 94: 1996.
- Tamiya, S.; Etoh, K.; Suzushima, H.; Takatsuki, K. and Matsuoka, M. (1998):** Mutation of CD95 (Fas/APO-1) gene in adult T-cell leukemia cells. *Blood*, 41: 3935-3942.
- Thompson, C.B. (1995):** Apoptosis in the pathogenesis and treatment of disease. *Science*; 267: 1456-1462.
- Todd, R.; Howard, J. and Holcombe, E. (1997):** Principle and practice of pediatric oncology; Pizzo, 18: 463.
- Trueworthy, R.; Shuster, J.; Look, T. et al. (1992):** Ploidy of lymphoblasts is the strongest predictor of treatment outcome in progenitor cell acute lymphoblastic leukemia. *J. Clin. Oncol.*, 10: 606.

Tubergen, D.; Gilchrist, G.; Coccia, P. et al. (1993): The interaction of central nervous system therapy and systemic therapy in the prevention of CNS relapse in acute lymphoblastic leukemia? Proc. Am. Soc. Clin. Oncol., 10: 233.

Tucker, M.; Meadows, A.; Boke, J.J.; Stovall, M.; Oberlin, O.; Stone, B.J.; Birch, J.; Voute, P.A.; Hoover, R.N. and Fraumeni, J.F. (1987): Leukemia after therapy with alkylating agents for childhood cancer. J. Nat. Cancer Inst., 78: 459.

Uderzo, C.; Zurelo, M.; Adamoli, L. et al. (1990): Treatment of overt isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. J. Clin. Oncol., 8: 672.

Uderzo, R.; Rondelli, R.; Dini, G. et al. (1995): High dose vincristine, fractionated total body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: a 7-year Italian multicentre study. Br. J. Haematol., 89: 790.

VanZee, K.J.; Kohno, T.; Fischer, E.; Rock, C.S.; Moldawer, L.L. and Lowry, S.F. (1992): Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proceeding of the National Academy of Sciences of the United States of America, 89: 4845-4849.

Viana, M.; Muro, M.; Ramos, G. et al. (1994): Malnutrition as a prognostic factor in ALL: a multivariate analysis. Arch. Dis. Child, 71: 304.

Von Reyher, U.; Srater, J.; Kittstein, W.; Gscwendt, M.; Krammer, P.H. and Moller, P. (1998): Colon carcinoma cells use different mechanism to escape CD95-mediated apoptosis. Cancer Research, 58: 526-534.

- Watanabe-Fukunaga, R.; Brannan, C.I.; Copeland, N.G.; Jenkins, N.A. and Nagata, S. (1995):** Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. *Nature*, 356: 314-317.
- Wertheimer, N.; Savitz, D. and Leeper, E. (1995):** Childhood cancer in relation to indicators of magnetic fields from ground current sources. *Bioelectromagnetics*, 6: 86.
- Wexler, L.; Andrich, M.; Venzon, D. et al. (1996):** Randomized trial of the cardioprotective agent. Cardioxan (ICRF-187) in pediatric sarcoma patients treated with doxorubicin. *J. Clin. Oncol.*, 14: 362.
- Whittaker, J.A. et al. (1993):** Leukaemia 2nd edition, Blackwell Scientific Publication, Oxford.
- Whitlock, J.A. and Gaynon, P.S. (1999):** Acute lymphoblastic leukemia: In Lee GR, Foerster J, Lukens J et al. (eds): *Wintrobe's clinical hematology*, 10th ed Chapter 87: 2241, Williams and Wilkins.
- Wiernik, P.H.; Canellos, G.P.; Kyle, R.A. and Schiffer, C.A. (1995):** Neoplastic diseases in the blood. Churchill Livingstone, Edinburgh.
- Wiersma, S.; Ortega, J.; Sobel, E. and Weinberg, K. (1991):** Clinical importance of myeloid-antigen expression in ALL of childhood. *N. Engl. J. Med.*, 324: 800.
- William, M.; William, S.; Richard, E.; Robert, M. and Hal, B. (2000):** The leukemia. *Nelson*, Vol. (14), 502: 1543-1548.
- Yeazel, M.; Buckley, J. and Wood, W. (1995):** History of maternal fetal loss and increased risk of childhood acute leukemia at an early age. *Cancer*, 75: 1718.
- Zaki, A. (1993):** Impact of immunophenotyping and karyotype on achievement of complete remission in pediatric acute lymphoblastic leukemia. M.Sc. Thesis in Pediatrics Cairo University.

Zhou, M.; Gu, L.; Yeager, A.M. and Findley, H.W. (1998): Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with mutant P53 phenotype and absence of BCL-2 expression. *Leukemia* 12(11): 1756-63.

Zittoun, R.A. (ed) (1993): Chemotherapy of malignant blood disease. *Clinical Haematology*, 4, 1-246.